Seitz, Tina

[["dc.bibliographiccitation.firstpage","2035"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","2045"],["dc.bibliographiccitation.volume","147"],["dc.contributor.author","Huber, D."],["dc.contributor.author","Seitz, S."],["dc.contributor.author","Kast, K."],["dc.contributor.author","Emons, G."],["dc.contributor.author","Ortmann, O."],["dc.date.accessioned","2021-06-01T09:42:51Z"],["dc.date.available","2021-06-01T09:42:51Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Purpose BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is associated with a decrease in risk for tubal and ovarian cancer. Hormone replacement therapy (HRT) may increase breast, ovarian, and endometrial cancer risk in the general population. This review analyses the published data on HRT and risk of cancer in BRCA mutation carriers with and without RRBSO. Methods We included all relevant articles published in English from 1995 to October 2020. Sources were identified through a search on PubMed and Cochrane Library. Results We included one case–control and one retrospective cohort study on ovarian and one case–control study on endometrial cancer risk and HRT in BRCA mutation carriers. Regarding breast cancer risk, one case–control study on BRCA mutation carriers with and without RRBSO and one case–control study, one Markov chain decision model, two prospective cohort studies, and one metaanalysis on carriers after RRBSO were included. For ovarian cancer, results were ambiguous. For breast cancer, most studies did not find an adverse effect associated with HRT. However, some of the studies found a risk modification associated with different formulations and duration of use. Conclusion Although data are limited, HRT does not seem to have a relevant effect on cancer risk in BRCA mutation carriers. RRBSO should not be postponed to avoid subsequent HRT in this population. Adequate HRT after RRBSO should be offered to avoid chronic diseases resulting from low estrogen levels. However, further data on the safety of different formulations are needed."],["dc.identifier.doi","10.1007/s00432-021-03629-z"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85374"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1432-1335"],["dc.relation.issn","0171-5216"],["dc.title","Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Naunyn-Schmiedeberg s Archives of Pharmacology"],["dc.bibliographiccitation.volume","388"],["dc.contributor.author","Seitz, Tina"],["dc.contributor.author","Bokelmann, Kristin"],["dc.contributor.author","Pereira, Joao N. dos Santos"],["dc.contributor.author","Mueller, T."],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Koepsell, Hermann"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.date.accessioned","2018-11-07T10:01:10Z"],["dc.date.available","2018-11-07T10:01:10Z"],["dc.date.issued","2015"],["dc.format.extent","S54"],["dc.identifier.isi","000359539100217"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37958"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","81st Annual Meeting of the Deutsche-Gesellschaft-fur-Experimentelle-und-Klinische-Pharmakologie-und Toxikologie-e-V"],["dc.relation.eventlocation","Kiel, GERMANY"],["dc.relation.issn","1432-1912"],["dc.relation.issn","0028-1298"],["dc.title","Does the apparently predictive haplotype Met408-Del420 really exist and how strong it affects OCT1 activity?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Biological Chemistry"],["dc.bibliographiccitation.volume","398"],["dc.contributor.author","Chen, Jiayin"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Seitz, Tina"],["dc.contributor.author","Koenig, Joerg"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Chen, Xijing"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.format.extent","813"],["dc.identifier.doi","10.1515/hsz-2017-0129"],["dc.identifier.isi","000403093600009"],["dc.identifier.pmid","28291733"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42256"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Walter De Gruyter Gmbh"],["dc.relation.issn","1437-4315"],["dc.relation.issn","1431-6730"],["dc.title","Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families (vol 398, pg 237, 2017)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","S0021925822004148"],["dc.bibliographiccitation.firstpage","101974"],["dc.bibliographiccitation.journal","Journal of Biological Chemistry"],["dc.contributor.author","Meyer, Marleen J."],["dc.contributor.author","Schreier, Pascale C.F."],["dc.contributor.author","Basaran, Mert"],["dc.contributor.author","Vlasova, Stefaniia"],["dc.contributor.author","Seitz, Tina"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Zdrazil, Barbara"],["dc.contributor.author","Tzvetkov, Mladen V."],["dc.date.accessioned","2022-05-02T08:09:54Z"],["dc.date.available","2022-05-02T08:09:54Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1016/j.jbc.2022.101974"],["dc.identifier.pii","S0021925822004148"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107500"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.issn","0021-9258"],["dc.title","Amino acids in transmembrane helix 1 confer major functional differences between human and mouse orthologs of the polyspecific membrane transporter OCT1"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","868"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Clinical Pharmacology & Therapeutics"],["dc.bibliographiccitation.lastpage","878"],["dc.bibliographiccitation.volume","103"],["dc.contributor.author","Tzvetkov, Mladen V."],["dc.contributor.author","Matthaei, Johannes"],["dc.contributor.author","Pojar, Sherin"],["dc.contributor.author","Faltraco, Frank"],["dc.contributor.author","Vogler, Sabrina"],["dc.contributor.author","Prukop, Thomas"],["dc.contributor.author","Seitz, Tina"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.date.accessioned","2020-12-10T14:06:00Z"],["dc.date.available","2020-12-10T14:06:00Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1002/cpt.v103.5"],["dc.identifier.issn","0009-9236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69742"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency"],["dc.title.alternative","OCT1 deficiency and fenoterol toxicity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","875"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Archives of Gynecology and Obstetrics"],["dc.bibliographiccitation.lastpage","884"],["dc.bibliographiccitation.volume","301"],["dc.contributor.author","Huber, D."],["dc.contributor.author","Seitz, S."],["dc.contributor.author","Kast, K."],["dc.contributor.author","Emons, G."],["dc.contributor.author","Ortmann, O."],["dc.date.accessioned","2020-12-10T14:10:29Z"],["dc.date.available","2020-12-10T14:10:29Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00404-020-05458-w"],["dc.identifier.eissn","1432-0711"],["dc.identifier.issn","0932-0067"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70774"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.haserratum","/handle/2/94647"],["dc.title","Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1427"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","1429"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Seitz, Tina"],["dc.contributor.author","Bokelmann, Kristin"],["dc.contributor.author","Mueller, Thomas"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Koepsell, Hermann"],["dc.date.accessioned","2018-11-07T09:43:36Z"],["dc.date.available","2018-11-07T09:43:36Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1182/blood-2013-11-535864"],["dc.identifier.isi","000335839300028"],["dc.identifier.pmid","24578499"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34216"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Archives of Gynecology and Obstetrics"],["dc.contributor.author","Huber, D."],["dc.contributor.author","Seitz, S."],["dc.contributor.author","Kast, K."],["dc.contributor.author","Emons, G."],["dc.contributor.author","Ortmann, O."],["dc.date.accessioned","2021-12-01T09:23:25Z"],["dc.date.available","2021-12-01T09:23:25Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00404-021-06266-6"],["dc.identifier.pii","6266"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94647"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1432-0711"],["dc.relation.iserratumof","/handle/2/70774"],["dc.relation.issn","0932-0067"],["dc.title","Correction to: Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","erratum_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","237"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Biological Chemistry"],["dc.bibliographiccitation.lastpage","249"],["dc.bibliographiccitation.volume","398"],["dc.contributor.author","Chen, Jiayin"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Seitz, Tina"],["dc.contributor.author","Koenig, Joerg"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Chen, Xijing"],["dc.date.accessioned","2018-11-07T10:28:12Z"],["dc.date.available","2018-11-07T10:28:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Tropane alkaloids and their derivatives are anticholinergic drugs with narrow therapeutic range. Here we characterize the organic cation transporters from the SLC22 (OCT1, OCT2, and OCT3) and the SLC47 families (MATE1 and MATE2-K) as potential mediators of the renal and extra-renal excretion, the two major roads of elimination of these substances. All analyzed compounds inhibited and the quaternary amine derivatives ipratropium and trospium were strongly transported by OCTs and MATEs. Overexpression of OCTs or MATEs in HEK293 cells resulted in an up to 63-fold increase in the uptake of ipratropium (K-m of 0.32 mu m to OCT2 and V-max of 3.34 nmol x mg protein(-1) x min(-1) to MATE1). The transcellular transport of ipratropium was 16-fold higher in OCT2-MATE1 and 10-fold higher in OCT1-MATE1 overexpressing compared to control MDCKII cells. Genetic polymorphisms in OCT1 and OCT2 affected ipratropium uptake and clinically relevant concentration of ondansetron and pyrithiamine inhibited ipratropium uptake via MATEs by more than 90%. This study suggests that OCT1, OCT2 and MATEs may be strongly involved in the renal and extra-renal elimination of ipratropium and other quaternary amine alkaloids. These substances have a notoriously narrow therapeutic range and the drug-drug interactions suggested here should be further critically evaluated in humans."],["dc.identifier.doi","10.1515/hsz-2016-0236"],["dc.identifier.isi","000391201600009"],["dc.identifier.pmid","27676604"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43371"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Walter De Gruyter Gmbh"],["dc.relation.issn","1437-4315"],["dc.relation.issn","1431-6730"],["dc.title","Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","715"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Archives of Gynecology and Obstetrics"],["dc.bibliographiccitation.lastpage","720"],["dc.bibliographiccitation.volume","302"],["dc.contributor.author","Huber, D."],["dc.contributor.author","Seitz, S."],["dc.contributor.author","Kast, K."],["dc.contributor.author","Emons, G."],["dc.contributor.author","Ortmann, O."],["dc.date.accessioned","2021-04-14T08:24:46Z"],["dc.date.available","2021-04-14T08:24:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00404-020-05690-4"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81416"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1432-0711"],["dc.relation.issn","0932-0067"],["dc.title","Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]